Research Park Triangle, N.C.-based Asensus announced last month that the company would change its name from TransEnterix to Asensus Surgical and introduce a new surgery category. The company aims to enter a new era of performance-guided surgery focused on digitizing the interface between surgeons and patients to bring clinical intelligence that may enable better outcomes and, potentially, a new standard of surgery.
Effective today, the company’s stock is trading on the New York Stock Exchange American under the ASXC ticker. No actions are needed from current stockholders relative to the change. Shares of ASXC are currently trading at $4.08 per share, having closed yesterday down -10.1%.
Just this week, Asensus garnered its first regulatory nod since the name change, winning expanded FDA clearance for general surgery with its Senhance surgical system, a first-of-its-kind digital laparoscopic platform that leverages augmented intelligence to provide strong performance and positive patient outcomes through machine learning.